Oruka Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ORKA$104.56+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $83,572 | $61,575 |
| Marketable securities, current | 265,522 | 314,073 |
| Prepaid expenses and other current assets | 2,989 | 1,221 |
| Total current assets | 352,083 | 376,869 |
| Marketable securities, long-term | 23,953 | 18,069 |
| Property and equipment, net | 159 | 162 |
| Operating lease right-of-use assets | 814 | 876 |
| Other non-current assets | 103 | 43 |
| Total assets | $377,112 | $396,019 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,545 | $3,462 |
| Accrued expenses and other current liabilities | 5,663 | 3,346 |
| Operating lease liability, current | 283 | 213 |
| Related party common stock warrant liability | 1,415 | — |
| Related party accounts payable and other current liabilities | 817 | 6,022 |
| Total current liabilities | 11,723 | 13,043 |
| Operating lease liability, non-current | 664 | 755 |
| Total liabilities | 12,387 | 13,798 |
| Commitment and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of March 31, 2025 and December 31, 2024; 137,138 shares issued and outstanding as of March 31, 2025 and December 31, 2024 | 2,931 | 2,931 |
| Common stock, $0.001 par value; 545,000,000 shares authorized, 37,440,510 shares issued and outstanding as of March 31, 2025 and December 31, 2024 | 37 | 37 |
| Additional paid-in capital | 466,486 | 463,018 |
| Accumulated other comprehensive loss | (6) | (41) |
| Accumulated deficit | (104,723) | (83,724) |
| Total stockholders’ equity | 364,725 | 382,221 |
| Total liabilities, convertible preferred stock and stockholders’ equity | $377,112 | $396,019 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.